HART NYLI Healthy Hearts ETF

 

As filed with the Securities and Exchange Commission on November 16, 2023

 

Registration No. 333-

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM S-8

 

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

 

Harvard Apparatus Regenerative Technology, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware		45-5210462
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

 

84 October Hill Road, Suite 11 Holliston, MA		01746
(Address of Principal Executive Offices)		(Zip Code)

 

Amended and Restated Equity Incentive Plan

(Full title of the plan)

 

Junli (Jerry) He

Chairman of the Board of Directors and Chief Executive Officer

Harvard Apparatus Regenerative Technology, Inc.

84 October Hill Road, Suite 11, Holliston, MA 01746

(Name and address of agent for service)

 

(774) 233-7300

(Telephone number, including area code, of agent for service)

 

With copies to:

 

Chad J. Porter, Esq.

Burns & Levinson LLP

125 High Street

Boston, Massachusetts 02110

(617) 345-3000

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (check one)

 

Large Accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

 

 

INCORPORATION BY REFERENCE OF PRIOR REGISTRATION STATEMENTS

 

Harvard Apparatus Regenerative Technology, Inc., a Delaware corporation (the “Registrant”) is filing this Registration Statement on Form S-8 for the purpose of registering an additional 4,000,000 shares of its common stock, par value $0.001 per share (the “Common Stock”), issuable to eligible persons under the Registrant’s Amended and Restated Equity Incentive Plan, as amended (the “Plan”) pursuant to an amendment to the Plan approved by the Registrant’s stockholders on July 19, 2023.

 

Pursuant to Instruction E to Form S-8, the Registrant incorporates by reference into this Registration Statement, except to the extent supplemented, amended or superseded by the information set forth herein, the entire contents of its Registration Statements on Form S-8 previously filed with respect to the Plan, including those filed with the Securities and Exchange Commission on October 31, 2013 (Registration No. 333-192027), on March 30, 2015 (Registration No. 333-203105), on August 8, 2016 (Registration No. 333-212993), on August 15, 2017 (Registration No. 333-219988), on May 31, 2018 (Registration No. 333-225336) and on June 22, 2020 (Registration No. 333-239346).

 

 

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

 

Item 8. Exhibits.

 

Number		Description
4.1(1)		Amended and Restated Certificate of Incorporation of the Registrant dated July 31, 2018.
4.2(2)		Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant dated March 30, 2016.
4.3(3)		Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant dated May 26, 2016.
4.4(4)		Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant dated April 26, 2017.
4.5(5)		Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant dated December 21, 2017.
4.6(6)		Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant dated May 24, 2019.
4.7(7)		Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant effective as of July 20, 2023.
4.8(8)		Third Amended and Restated By-laws of the Registrant.
4.9(9)		Amended and Restated Equity Incentive Plan, as amended.
4.10(10)		Specimen Stock Certificate pertaining to shares of common stock.
5.1*		Opinion of Burns & Levinson LLP, counsel to the Registrant.
23.1*		Consent of Marcum LLP.
23.2*		Consent of Wei, Wei & Co., LLP.
23.3*		Consent of Burns & Levinson LLP (included in Exhibit 5.1).
24.1*		Power of attorney (included on the signature pages of this registration statement)
107*		Calculation of Filing Fee Table.

 

* Filed herewith.

 

(1)	Previously filed with the Securities and Exchange Commission as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on July 20, 2023 and incorporated herein by reference.
(1)	Previously filed with the Securities and Exchange Commission as Exhibit 3.1 to the Registrant’s Registration Statement on Form 10 filed on July 31, 2013, as amended (File No. 001-35853) and incorporated herein by reference.
(2)	Previously filed with the Securities and Exchange Commission as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on March 31, 2016 and incorporated herein by reference.
(3)	Previously filed with the Securities and Exchange Commission as Exhibit 3.3 to the Registrant’s Annual Report on Form 10-K filed on March 17, 2017 and incorporated herein by reference.
(4)	Previously filed with the Securities and Exchange Commission as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on April 27, 2017 and incorporated herein by reference.
(5)	Previously filed with the Securities and Exchange Commission as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on December 22, 2017 and incorporated herein by reference.
(6)	Previously filed with the Securities and Exchange Commission as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on May 28, 2019 and incorporated herein by reference.
(7)	Previously filed with the Securities and Exchange Commission as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on July 20, 2023 and incorporated herein by reference.
(8)	Previously filed with the Securities and Exchange Commission as Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed on July 20, 2023 and incorporated herein by reference.
(9)	Previously filed with the Securities and Exchange Commission as Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q filed on November 13, 2023 and incorporated herein by reference.
(10)	Previously filed with the Securities and Exchange Commission as Exhibit 4.1 to the Registrant’s Registration Statement on Form 10 filed on July 31, 2013, as amended (File No. 001-35853) and incorporated herein by reference.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the Town of Holliston, Commonwealth of Massachusetts, on this 16th day of November, 2023.

 

	HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC.
	By:	/s/ Joseph Damasio
		Joseph Damasio
		Chief Financial Officer

 

POWER OF ATTORNEY

 

KNOW ALL PERSONS BY THESE PRESENTS that each individual whose signature appears below constitutes and appoints Junli (Jerry) He and Joseph Damasio, and each of them, his true and lawful attorneys-in-fact and agents with full power of substitution, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Harvard Apparatus Regenerative Technology, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.

 

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature		Title		Date
/s/ Junli (Jerry) He		Chief Executive Officer and Chairman of the Board of Directors		November 16, 2023
Junli (Jerry) He		(Principal Executive Officer)
/s/ Joseph Damasio		Chief Financial Officer		November 16, 2023
Joseph Damasio		(Principal Financial Officer and Principal Accounting Officer)
/s/ Jason Jing Chen		Vice Chairman		November 16, 2023
Jason Jing Chen
/s/ James Shmerling		Director		November 16, 2023
James Shmerling
/s/ Ting Li		Director		November 16, 2023
Ting Li
/s/ David Green		Director		November 16, 2023
David Green
/s/ Ronald Packard		Director		November 16, 2023
Ronald Packard
/s/ Herman Sanchez		Director		November 16, 2023
Herman Sanchez

 

 

 

Exhibit 5.1

 

November 16, 2023

 

Harvard Apparatus Regenerative Technology, Inc.

84 October Hill Road, Suite 11

Holliston, MA 01746

 

Re: Securities Being Registered under Registration Statement on Form S-8

 

Ladies and Gentlemen:

 

We have assisted in the preparation of a Registration Statement on Form S-8 (the “Registration Statement”) to be filed with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”), relating to an aggregate of 4,000,000 shares of common stock, $0.01 par value per share (the “Shares”), of Harvard Apparatus Regenerative Technology, Inc., a Delaware corporation (the “Company”), issuable under the Company’s Amended and Restated Equity Incentive Plan, as amended (the “Plan”).

 

We have reviewed such documents and made such examination of law as we have deemed appropriate to give the opinion expressed below. We have relied, without independent verification, as to matters of fact material to the opinion set forth below, on certificates of officers of the Company.

 

The opinion expressed below is limited to the Delaware General Corporation Law (which includes applicable provisions of the Delaware Constitution and reported judicial decisions interpreting the Delaware General Corporation Law and the Delaware Constitution).

 

For purposes of the opinion expressed below, we have assumed that a sufficient number of authorized but unissued shares of the Company’s common stock will be available for issuance when the Shares are issued.

 

Based on the foregoing, we are of the opinion that the Shares have been duly authorized and, upon issuance and delivery against payment therefor in accordance with the terms of the Plan, will be validly issued, fully paid and nonassessable.

 

We hereby consent to the inclusion of this opinion as Exhibit 5.1 to the Registration Statement. In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.

 

Very truly yours,

 

BURNS & LEVINSON LLP

 

/s/ BURNS & LEVINSON LLP

 

 

 

 

Exhibit 23.1

 

Independent Registered Public Accounting Firm’s Consent

 

We consent to the inclusion in the Registration Statement of Harvard Apparatus Regenerative Technology, Inc. (formerly Biostage, Inc.) on Form S-8 of our report dated March 30, 2023, which includes an explanatory paragraph as to Harvard Apparatus Regenerative Technology, Inc.’s ability to continue as a going concern, with respect to our audit of the financial statements of Harvard Apparatus Regenerative Technology, Inc. as of December 31, 2022 and for the year ended December 31, 2022, appearing in the Annual Report of Form 10-K of Harvard Apparatus Regenerative Technology, Inc. for the year ended December 31, 2022.

 

/s/ Marcum LLP

 

Marcum LLP

Boston, MA

November 16, 2023

 

 

 

Exhibit 23.2

 

 

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 of our report dated March 31, 2022, relating to the consolidated financial statements of Harvard Apparatus Regenerative Technology, Inc. (formerly Biostage Inc.) and subsidiaries as of and for the year ended December 31, 2021, and to the reference to us under the heading “Experts” in such Registration Statement.

 

/s/ Wei, Wei & Co., LLP

 

Flushing, New York

November 16, 2023

 

 

 

Exhibit 107

 

Calculation of Filing Fee Table

 

FORM S-8

(Form Type)

 

Harvard Apparatus Regenerative Technology, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

Newly Registered Securities

 

		Security Type		Security Class Title		Fee Calculation Rule		Amount Registered(1)				Proposed Maximum Offering Price Per Unit				Maximum Aggregate Offering Price				Fee Rate				Amount of Registration Fee(2)
Fees to be paid		Equity		Common Stock, par value $0.01 per share		Rules 457(c) and 457(h)			4,000,000			$	5.82			$	23,280,000				$147.60 per $1,000,000			$	3,436.13
Total Offering Amounts																								$	3,436.13
Total Fee Offsets																								$	—
Net Fee Due																								$	3,436.13

 

(1)	Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of the Registrant’s Common Stock that become issuable under the Registrant’s Amended and Restated Equity Incentive Plan, as amended (the “Equity Incentive Plan”) which are available for issuance pursuant to an amendment to the Equity Incentive Plan approved by the Registrant’s stockholders on July 19, 2023, plus such indeterminate number of additional shares of Common Stock as may be required pursuant to the Equity Incentive Plan by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected that results in an increase to the number of outstanding shares of the Registrant’s Common Stock, as applicable.
(2)	Estimated in accordance with Rule 457(c) and Rule 457(h) under the Securities Act, solely for the purpose of calculating the registration fee. Such computation is based on the average of the high and low prices of the Registrant’s Common Stock as reported on the OTCQB Venture Market on November 14, 2023 with respect to trading under the ticker symbol “HRGN”.

 

 

---